Arnold Bloch Leibler has advised Australian medical technology company Epiminder Limited on its successful debut on the Australian Securities Exchange (ASX), following a $125 million initial public offering (IPO) with a market capitalisation of $325 million.
Founded in 2018 out of a research collaboration between the Bionics Institute, the University of Melbourne, St Vincent’s Hospital Melbourne and Cochlear, Epiminder has developed the Minder system, a minimally invasive implantable EEG device designed to provide continuous, long-term monitoring for people with epilepsy. The device, manufactured with the support of major shareholder Cochlear, aims to significantly improve treatment outcomes and reduce healthcare costs for the more than 52 million people living with epilepsy worldwide.
As reported in the Australian Financial Review, Epiminder’s listing comes during a period of volatility for the Australian market and represents one of the few biotech IPOs in recent years, underscoring strong investor confidence in the company’s technology and growth potential. Proceeds from the IPO will support Epiminder’s commercial rollout, including the planned launch of its G0 Minder system in the United States during the first half of 2026, following FDA approval earlier this year.
Arnold Bloch Leibler’s transaction team, led by Capital Markets and Corporate & M&A partner Jason van Grieken, included:
- Commercial: Ryan Taylor (Senior Associate), Aaron Low (Lawyer), Brendan Courtney (Lawyer), Noah Abelman (Lawyer), Kaitie Boyd (Lawyer), Tamara Wilson (Advisor), Robyn Kalkhoven (Law Graduate)
- Tax: Jonathan Ortner (Partner) and George Bassil (Senior Associate)
- Workplace Advisory: Rachel Soh (Partner) and Edwina Lu (Lawyer)
Jason van Grieken commented: “Epiminder’s IPO marks a pivotal milestone for one of Australia’s most exciting medical device companies. The Minder system has the potential to transform how epilepsy is monitored and understood globally. We are proud to have supported the Epiminder team through this significant step and look forward to the company’s next phase of growth.”
Epiminder’s listing adds to ABL’s long-standing track record advising Australian innovators and high-growth technology companies on capital raisings, strategic transactions and public market listings.
